Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Am J Med Sci. 2016 Jan 29;351(4):416–419. doi: 10.1016/j.amjms.2016.01.013

Table 2.

PSA Endpoints for Prostate Cancer Patients with Metformin Versus Controls

Variable Non-Metformin
n = 149
M ± SD or %		 Metformin
n = 138
M ± SD or %		 Cohen’s d p-value
PSA nadir, ng/mL 0.28 ± 0.60 0.28 ± 0.54 .013 .915
PSA final, ng/mL a 0.84 ± 1.38 0.57 ± 0.78 .244 .067
PSA velocity, ng/mL/year a 0.27 ± 0.82 0.12 ± 0.31 .240 .076
a

n = 112, 116 for non-metformin and metformin respectively. Those who had time since nadir = 0 or PSA > 10 were excluded.